Johnson & Johnson Announced Updated Results From The Investigational Phase 1b RedirecTT-1 Study Evaluating The First-ever Bispecific Antibody Combination Of TALVEY And TECVAYLI Suggests High Response Rates And Durable Responses In Triple-Class Refractory Patients With Relapsed Or Refractory Multiple Myeloma, Including Those With Extramedullary Disease
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson announced promising results from their Phase 1b RedirecTT-1 study, which evaluated a bispecific antibody combination of TALVEY and TECVAYLI for treating relapsed or refractory multiple myeloma. The study showed high response rates and durable responses with a safety profile consistent with monotherapies.
September 27, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson's Phase 1b study results for TALVEY and TECVAYLI show high response rates in treating multiple myeloma, potentially boosting investor confidence in their oncology pipeline.
The positive results from the Phase 1b study suggest that Johnson & Johnson's bispecific antibody combination could be effective in treating multiple myeloma, which may enhance the company's oncology portfolio and investor sentiment. The consistent safety profile further supports the potential for successful future trials and market approval.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90